Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
BLISS GVS PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BLISS GVS PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
BLISS GVS PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 91 | 325 | - | |
Low | Rs | 67 | 234 | - | |
Sales per share (Unadj.) | Rs | 72.2 | 96.6 | - | |
Earnings per share (Unadj.) | Rs | 7.4 | -24.3 | - | |
Cash flow per share (Unadj.) | Rs | 9.2 | -20.2 | - | |
Dividends per share (Unadj.) | Rs | 0.50 | 0 | - | |
Avg Dividend yield | % | 0.6 | 0 | - | |
Book value per share (Unadj.) | Rs | 84.0 | 75.8 | - | |
Shares outstanding (eoy) | m | 104.15 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.1 | 2.9 | 38.0% | |
Avg P/E ratio | x | 10.8 | -11.5 | -93.8% | |
P/CF ratio (eoy) | x | 8.7 | -13.9 | -62.5% | |
Price / Book Value ratio | x | 0.9 | 3.7 | 25.6% | |
Dividend payout | % | 6.8 | 0 | - | |
Avg Mkt Cap | Rs m | 8,262 | 47,183 | 17.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 862 | 2,961 | 29.1% | |
Avg. sales/employee | Rs Th | 0 | 3,798.6 | - | |
Avg. wages/employee | Rs Th | 0 | 689.8 | - | |
Avg. net profit/employee | Rs Th | 0 | -957.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 7,516 | 16,307 | 46.1% | |
Other income | Rs m | 178 | 114 | 155.8% | |
Total revenues | Rs m | 7,694 | 16,421 | 46.9% | |
Gross profit | Rs m | 1,173 | -2,826 | -41.5% | |
Depreciation | Rs m | 187 | 704 | 26.5% | |
Interest | Rs m | 104 | 442 | 23.5% | |
Profit before tax | Rs m | 1,061 | -3,857 | -27.5% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 293 | 241 | 121.7% | |
Profit after tax | Rs m | 767 | -4,109 | -18.7% | |
Gross profit margin | % | 15.6 | -17.3 | -90.1% | |
Effective tax rate | % | 27.7 | -6.2 | -442.6% | |
Net profit margin | % | 10.2 | -25.2 | -40.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,974 | 11,944 | 58.4% | |
Current liabilities | Rs m | 1,933 | 6,720 | 28.8% | |
Net working cap to sales | % | 67.1 | 32.0 | 209.4% | |
Current ratio | x | 3.6 | 1.8 | 203.0% | |
Inventory Days | Days | 39 | 111 | 34.8% | |
Debtors Days | Days | 1,871 | 124 | 1,509.2% | |
Net fixed assets | Rs m | 4,562 | 6,962 | 65.5% | |
Share capital | Rs m | 104 | 76 | 137.6% | |
Net worth | Rs m | 8,750 | 12,799 | 68.4% | |
Long term debt | Rs m | 407 | 4,498 | 9.0% | |
Total assets | Rs m | 11,535 | 24,179 | 47.7% | |
Interest coverage | x | 11.2 | -7.7 | -145.3% | |
Debt to equity ratio | x | 0 | 0.4 | 13.2% | |
Sales to assets ratio | x | 0.7 | 0.7 | 96.6% | |
Return on assets | % | 7.6 | -15.2 | -49.8% | |
Return on equity | % | 8.8 | -32.1 | -27.3% | |
Return on capital | % | 12.7 | -19.8 | -64.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 343 | 1,392 | 24.7% | |
From Investments | Rs m | -78 | -427 | 18.1% | |
From Financial Activity | Rs m | -249 | 4,082 | -6.1% | |
Net Cashflow | Rs m | 30 | 5,047 | 0.6% |
Compare BLISS GVS PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare BLISS GVS PHARMA With: BACIL PHARMA SEQUENT SCIENTIFIC SYNCOM HEALTHCARE ASTRAZENECA PHARMA CONCORD DRUGS
After opening the day on positive note, Indian share markets reversed the trend as the session progressed and ended lower.